The rise and subsequent decline of IBM Watson Health represents a seminal case study in the intersection of legacy industrial computing, the aggressive financialization of medical data, and the premature deployment of narrow artificial intelligence in high-stakes clinical environments. Once heralded as the panacea for the complexities of modern oncology, Watson Health was positioned by IBM leadership as a "moonshot" capable of democratizing elite medical expertise through the